

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Benefit Assessment under Section 35a SGB V on Melphalan flufenamide (new therapeutic indication: multiple myeloma, refractory, after 2 prior therapies, in combination with dexamethasone)

of 4 April 2024

The Federal Joint Committee (G-BA) decided the following at its session on 4 April 2024:

- I. The benefit assessment procedure commenced on 15 January 2024 for melphalan flufenamide according to Section 35a paragraph 1 SGB V for a new therapeutic indication (multiple myeloma, refractory, after 2 prior therapies, combination with dexamethasone) is suspended.
- II. The resolution will enter into force on the day of its publication on the internet on the G-BA website on 4 April 2024.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 4 April 2024

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken